Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 200 clinical trials
Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC

Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC)

psychiatric disorder
cholangiocarcinoma
carcinoma
antibiotics
aptt
  • 2 views
  • 26 Jan, 2021
  • 1 location
Neoadjuvant Therapy in Biliary Adenocarcinoma

Feasibility of neoadjuvant therapy in resectable biliary adenocarcinoma.

  • 0 views
  • 31 Mar, 2021
  • 1 location
Tislelizumab(Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

The aim of this study is to assess the R0 resection rate of tislelizumab combined with Lenvatinib and Gemox chemotherapy in the conversion therapy of potentially resectable locally advanced BTC.

  • 0 views
  • 19 Dec, 2021
  • 1 location
Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

CTLA-4 Inhibitor Tremelimumab in patients with intrahepatic Biliary Tract Cancer

hormone therapy
hepatitis b surface antigen
biliary tract cancer
durvalumab
cancer
  • 1 views
  • 04 Mar, 2021
  • 1 location
Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers

The investigators design a phase II clinical study to explore the efficacy and safety of toripalimab plus lenvatinib as a second-line treatment in patients with advanced biliary tract cancers

  • 0 views
  • 26 Jan, 2021
  • 1 location
Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer

This is open-label, phase II study enrolling advanced BTC patients who have failed to 1st-line chemotherapy.

  • 0 views
  • 03 Feb, 2021
  • 1 location
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

This phase II trial studies how well olaparib works in treating patients with biliary tract cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair gene

tumor cells
blood transfusion
olaparib
measurable disease
cancer
  • 0 views
  • 12 Jan, 2022
  • 4 locations
Combination of Gemcitabine Oxaliplatin Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer

overall survival; Main characteristics of enrolled patients: Patients with initially unresectable biliary tract cancer; Interventions: Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab

  • 0 views
  • 15 Aug, 2021
  • 1 location
Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma

There is no proven adjuvant treatment after curative surgical resection in patients with cholangiocarcinoma, although previous meta-analysis suggested potential survival benefit of adjuvant chemotherapy or radiotherapy in patients with lymph node-positive resected cholangiocarcinoma. Despite of lack of level 1 evidence and no data which regimen is optimal, adjuvant chemotherapy is …

neutrophil count
cholangiocarcinoma
cancer
serum total bilirubin
malignant disease
  • 15 views
  • 24 Jan, 2021
  • 1 location
Study of Pembrolizumab Following TACE in Primary Liver Carcinoma

Open label, single arm, multi-centre study of pembrolizumab following trans-arterial chemoembolization (TACE). Twenty-six to 32 evaluable participants with primary liver cancer (hepatocellular cancer; HCC) will be assessed. The primary objective is to determine the safety and tolerability of pembrolizumab following TACE. The secondary objective is to evaluate the efficacy of …

  • 0 views
  • 22 Feb, 2021
  • 1 location